Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Inflammatory bowel disease (IBD) is a disease-specific risk factor for incident and recurrent venous thromboembolism (VTE). The reasons are acquired, multifactorial, and related to prothrombotic aberrations during active disease, although the mechanisms remain incompletely elucidated. VTE represents a potentially life-threatening extraintestinal manifestation of IBD, but the associated morbidity and mortality can be reduced by appropriate use of thromboprophylaxis. Nevertheless, despite international guidelines advocating thromboprophylaxis in hospitalised patients with IBD, practice is highly variable, since 65% of gastroenterologists may not use pharmacological VTE prophylaxis in hospitalised patients with acute severe colitis. Furthermore, there is no guidance on appropriate prophylaxis for ambulatory outpatients with active disease who are at an appreciable risk of VTE. Thus the question: are we tailoring thromboprophylaxis to those patients with IBD who are most at risk?

Original publication

DOI

10.1016/j.crohns.2013.09.007

Type

Journal article

Journal

J Crohns Colitis

Publication Date

02/2014

Volume

8

Pages

166 - 171

Keywords

Crohn's disease;, Inflammatory bowel disease;, Thrombosis;, Ulcerative colitis;, Venous thromboembolic disease, Anticoagulants, Guideline Adherence, Humans, Inflammatory Bowel Diseases, Patient Acuity, Patient Selection, Practice Guidelines as Topic, Prevalence, Risk Assessment, Risk Factors, Venous Thromboembolism